FDA approves a new Alzheimer’s drug from Eli Lilly

Evan Seigerman, BMO Capital Markets senior research analyst, joins ‘Squawk Box’ to discuss the FDA’s approval of Eli Lilly’s Alzheimer’s drug donanemab, how much revenue it could add to Elil LIlly’s bottom line, and the details behind the newly approved drug.